García-Sáez I, Reverter D, Vendrell J, Avilés F X, Coll M
Departament de Biologia Molecular i Cel.lular, Centre d'Investigació i Desenvolupament-CSIC, Jordi Girona 18-26, 08034 Barcelona, Spain.
EMBO J. 1997 Dec 1;16(23):6906-13. doi: 10.1093/emboj/16.23.6906.
The three-dimensional structure of human procarboxypeptidase A2 has been determined using X-ray crystallography at 1.8 A resolution. This is the first detailed structural report of a human pancreatic carboxypeptidase and of its zymogen. Human procarboxypeptidase A2 is formed by a pro-segment of 96 residues, which inhibits the enzyme, and a carboxypeptidase moiety of 305 residues. The pro-enzyme maintains the general fold when compared with other non-human counterparts. The globular part of the pro-segment docks into the enzyme moiety and shields the S2-S4 substrate binding sites, promoting inhibition. Interestingly, important differences are found in the pro-segment which allow the identification of the structural determinants of the diverse activation behaviours of procarboxypeptidases A1, B and A2, particularly of the latter. The benzylsuccinic inhibitor is able to diffuse into the active site of procarboxypeptidase A2 in the crystals. The structure of the zymogen-inhibitor complex has been solved at 2.2 A resolution. The inhibitor enters the active site through a channel formed at the interface between the pro-segment and the enzyme regions and interacts with important elements of the active site. The derived structural features explain the intrinsic activity of A1/A2 pro-enzymes for small substrates.
利用X射线晶体学在1.8埃分辨率下测定了人羧肽酶原A2的三维结构。这是关于人胰腺羧肽酶及其酶原的首份详细结构报告。人羧肽酶原A2由一个96个残基的前肽段(该前肽段抑制酶的活性)和一个305个残基的羧肽酶部分组成。与其他非人类对应物相比,该酶原保持了总体折叠结构。前肽段的球状部分对接至酶部分并屏蔽S2 - S4底物结合位点,从而促进抑制作用。有趣的是,在前肽段中发现了重要差异,这些差异有助于确定羧肽酶A1、B和A2(尤其是后者)不同激活行为的结构决定因素。苄基琥珀酸抑制剂能够扩散到晶体中人羧肽酶原A2的活性位点。已在2.2埃分辨率下解析了酶原 - 抑制剂复合物的结构。抑制剂通过在前肽段和酶区域之间的界面处形成的通道进入活性位点,并与活性位点的重要元件相互作用。所推导的结构特征解释了A1/A2酶原对小分子底物的内在活性。